Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: A translational study of the AIO colorectal study group

Clinical Colorectal Cancer

Volumn 10, Issue 1, 2011, Pages 24-29

  Baraniskin, Alexander ^a   Munding, Johanna ^b   Schulmann, Karsten ^a   Meier, Dominik ^a   Porschen, Rainer ^c   Arkenau, Hendrik Tobias ^d   Graeven, Ullrich ^e   Schmiegel, Wolff ^a,b,f   Tannapfel, Andrea ^b   Reinacher Schick, Anke ^a,f  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Hospital Bremen East   (Germany)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e KLINIKEN MARIA HILF GMBH   (Germany)

^f RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

5 Fluorouracil; DPC4; Immunohistochemistry; Prognostic marker

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; SMAD4 PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PLATINUM COMPLEX; SMAD4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; COLORECTAL TUMOR; DISEASE COURSE; GENETICS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOLOGY; PROGNOSIS; STATISTICS; TUMOR SUPPRESSOR GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SMAD4 PROTEIN; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 80053401516     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.3816/CCC.2011.n.003     Document Type: Article

References (18)

1. J Ferlay, P Autier, M Boniol et al. Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592 (Pubitemid 46359643)
2. JY Douillard, A Sobrero, C Carnaghi et al. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy Ann Oncol 14 2 suppl 2003 ii7 i12
3. JA Meyerhardt, RJ Mayer Systemic therapy for colorectal cancer N Engl J Med 352 2005 476 487
4. M Saunders, T Iveson Management of advanced colorectal cancer: state of the art Br J Cancer 95 2006 131 138 (Pubitemid 44050911)
5. J Leporrier, J Maurel, L Chicche et al. A population- based study of the incidence, management and prognosis of hepatis metastases from colorectal cancer Br J Surg 93 2006 465 474
6. GK Dy, TJ Hobday, G Nelson et al. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144 Clin Colorectal Cancer 8 2009 88 93
7. FT Bosman, P Yan, S Tejpar et al. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial Clin Cancer Res 15 2009 5528 5533
8. CH Köhne, D Cunningham, CF Di et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients Ann Oncol 13 2002 308 317 (Pubitemid 34704985)
9. K Derwinger, B Gustavsson A study of lymph node ratio in stage IV colorectal cancer World J Surg Oncol 6 2008 127
10. R Porschen, HT Arkenau, S Kubicka et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group J Clin Oncol 25 2007 4217 4223 (Pubitemid 47548561)
11. T Mikami, K Ookawa, T Shimoyama et al. KAI1, CAR, and Smad4 expression in the progression of colorectal tumor J Gastroenterol 36 2001 465 469 (Pubitemid 32747206)
12. H Alazzouzi, P Alhopuro, R Salovaara et al. SMAD4 as a prognostic marker in colorectal cancer Clin Cancer Res 11 2005 2606 2611 (Pubitemid 40569460)
13. A Reinacher-Schick, SE Baldus, B Romdhana et al. Loss of Smad4 correlates with loss of the invasion suppressor E-cadherin in advanced colorectal carcinomas J Pathol 202 2004 412 420 (Pubitemid 38456159)
14. R Salovaara, S Roth, A Loukola et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers Gut 51 2002 56 59 (Pubitemid 34717744)
15. A Maitra, K Molberg, J Albores-Saavedra et al. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease Am J Pathol 157 2000 1105 1111
16. K Takaku, M Oshima, H Miyoshi et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes Cell 92 1998 645 656 (Pubitemid 28141513)
17. M Miyaki, T Iijima, M Konishi et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis Oncogene 18 1999 3098 3103 (Pubitemid 29261230)
18. P Alhopuro, H Alazzouzi, H Sammalkorpl et al. SMAD4 levels and response to 5-fluorouracil in colorectal cancer Clin Cancer Res 11 2005 6311 6316 (Pubitemid 41262962)